Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vanessa Eaglin

Psychiatry Hilo, HI Medical Doctor

NPI 1194931196 CMS profile 235306

73 Puuhonu Pl, Suite 200, Hilo, HI 96720

Open in the dashboard

General payments

$1,952

117 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Vanessa Eaglin of Hilo, HI is reported in the CMS Open Payments database as having received $1,952 across 117 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $32 1
2023 General $244 11
2022 General $736 48
2021 General $527 35
2020 General $255 14
2019 General $157 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vanessa Eaglin
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Vanessa Eaglin were reported at $32. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Vanessa Eaglin Psychiatry median Middle half National median
2019 $157 $184 $59–$605 $163
2020 $255 $119 $36–$372 $114
2021 $527 $143 $43–$576 $132
2022 $736 $153 $50–$590 $149
2023 $244 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $32 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $542 31 payments
  2. Amgen Inc. $377 18 payments
  3. Biohaven Pharmaceutical Holding Company Ltd. $176 17 payments
  4. Janssen Pharmaceuticals, Inc $129 8 payments
  5. Biohaven Pharmaceuticals, Inc. $115 15 payments
  6. Arbor Pharmaceuticals, Inc. $111 6 payments
  7. AbbVie, Inc. $102 4 payments
  8. Otsuka America Pharmaceutical, Inc. $78 4 payments
  9. ITI, Inc. $76 3 payments
  10. Novo Nordisk Inc $64 3 payments
  11. Other $183 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,952 117 payments
Products named General payments · program years 2019–2025
  1. TRINTELLIX $514 29 payments
  2. NURTEC ODT $291 32 payments
  3. EVENITY $213 10 payments
  4. Prolia $213 10 payments
  5. Repatha $164 8 payments
  6. Otezla $164 8 payments
  7. XARELTO $129 8 payments
  8. REXULTI $78 4 payments
  9. CAPLYTA $76 3 payments
  10. Ozempic $64 3 payments
  11. Other $570 28 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

24

Median for Psychiatry: 574

Drug cost

$1,713

Median for Psychiatry: $27,624

Branded share of claims

100%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Risperidone Odt Risperidone Brand 24 $1,713

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Records

117 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Hawaii

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record